# A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

> **NCT02453685** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 335 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30
- **DRUG:** insulin glargine
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT02453685
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-31
- **Primary completion:** 2016-09-20
- **Final completion:** 2016-09-20
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453685, "A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02453685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*